Each dot is one of the 31 Pharma Services stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 6.0% and the median P/E 29.94. Pinned to the edge: 3 outliers on X and 2 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | TMOThermo Fisher Scientific | 8.3% | 36.63 | $259.44B | Life Sciences Tools |
| 2 | PFEPfizer | 1.3% | 40.85 | $164.73B | Pharmaceuticals |
| 3 | TEVATeva Pharmaceutical Industries | 2.7% | 102.64 | $51.97B | Generic Drugs |
| 4 | IQVIqvia Holdings | 8.8% | 31.30 | $43.67B | Contract Research |
| 5 | ZTSZoetis | 0.9% | 13.76 | $34.16B | Animal Health |
| 6 | LHLabcorp Holdings | 6.0% | 29.94 | $30.09B | Diagnostic Labs |
| 7 | WSTWest Pharmaceutical Services | 12.6% | 45.92 | $29.09B | Medical Supplies |
| 8 | STESteris | 8.1% | 31.11 | $25.67B | Medical Devices |
| 9 | IFFInternational Flavors & Fragrances | 24.3% | 36.61 | $20.32B | Specialty Chemicals |
| 10 | MEDPMedpace Holdings | 20.4% | 35.28 | $18.29B | Contract Research |
| 11 | CRLCharles River Laboratories International | -1.2% | 402.10OUT | $16.18B | Contract Research |
| 12 | LDOSLeidos Holdings | 2.7% | 11.41 | $15.93B | Defense |
| 13 | ICLRIcon | 1.8% | 34.02 | $14.90B | Contract Research |
| 14 | RDYDr Reddys Laboratories | -10.5% | 33.78 | $12.31B | Generic Drugs |
| 15 | DVADavita | 6.4% | 12.11 | $11.06B | Healthcare Services |
| 16 | PODDInsulet | 26.5% | 24.66 | $10.58B | Medical Devices |
| 17 | LNTHLantheus Holdings | 2.4% | 24.58 | $6.64B | Diagnostic Equipment |
| 18 | CAICaris Life Sciences | 61.5%OUT | 68.09 | $6.61B | Diagnostic Labs |
| 19 | LGNDLigand Pharmaceuticals | 1.0% | 119.78OUT | $6.18B | Biotechnology |
| 20 | OGNOrganon | -3.2% | 17.14 | $3.65B | Pharmaceuticals |
| 21 | ADMAAdma Biologics | 6.3% | 16.78 | $3.05B | Biotechnology |
| 22 | AMPHAmphastar Pharmaceuticals | 3.1% | 12.64 | $1.25B | Generic Drugs |
| 23 | IARTIntegra Lifesciences Holdings | 0.8% | 85.64 | $1.12B | Medical Devices |
| 24 | MGTXMeiraGTx Holdings | 1,366%OUT | 11.36 | $896.15M | Gene and Cell Therapy |
| 25 | EMBCEmbecta | -7.6% | 4.32 | $366.02M | Medical Devices |
| 26 | WDHWaterdrop | 76.3%OUT | 6.31 | $360.88M | Insurance Brokers |
| 27 | ELTPElite Pharmaceuticals | 17.8% | 5.90 | $355.46M | Generic Drugs |
| 28 | UTMDUtah Medical Products | -9.6% | 22.09 | $228.50M | Medical Devices |
| 29 | NSYSNortech Systems | 9.0% | 16.97 | $30.89M | Industrial Machinery |
| 30 | PLURPluri | 10.0% | 0.00 | $15.09M | Gene and Cell Therapy |
| 31 | PBSVPharma-Bio Serv | 3.3% | 45.53 | $11.45M | Consulting |
Among Pharma Services stocks, the largest companies growing revenue faster than the median (6.0%) while trading below the median P/E (29.94) are Davita (DVA), Insulet (PODD), Adma Biologics (ADMA), MeiraGTx Holdings (MGTX) and Waterdrop (WDH). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Charles River Laboratories International (CRL), Icon (ICLR) and Dr Reddys Laboratories (RDY).
The median P/E across the 31 Pharma Services stocks plotted is 29.94, with the middle half between 13.20 and 38.74.
The median is 6.0%, with the middle half between 1.2% and 11.3%.
The rank correlation (Spearman) is -0.17, a weak negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 3 companies are outliers on Revenue Growth (1y) (TTM) and 2 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry group is included unless you choose primary industry only. Nothing on this page is investment advice.